Insurers Dropping Top Valeant (VRX) Drugs - Wells Fargo's Maris

July 28, 2017 7:48 AM EDT
Get Alerts VRX Hot Sheet
Price: $23.40 --0%

Rating Summary:
    0 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Wells Fargo analyst David Maris notes insurers are dropping Valeant Pharmaceuticals (NYSE: VRX) top products.

Beginning July 1, 2017, United Healthcare formulary will no longer cover Valeant's Solodyn (Valeant's #3 branded Rx) and will also now exclude Retin-A brand (Valeant's #4 branded Rx). He estimates these two drugs represent approximately $214 million of 2016 Valeant's sales. He also notes Valeant's Glumetza (Valeant's #8 branded Rx) and Relistor were removed in July from CVS/Caremark's formulary, and these two drugs had approximately $119 million in 2016 revenues.

The analyst maintained his Underperform rating.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $17.13 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Hot Comments

Related Entities

Wells Fargo, David Maris